Similar articles

• Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.

  Andriulli A, Mangia A. Andriulli A, et al. N Engl J Med. 2007 Oct 18;357(16):1660; author reply 1661-2. doi: 10.1056/NEJMc072300. N Engl J Med. 2007. PMID: 17942881 No abstract available.
• Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

  Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D. Gallegos-Orozco JF, et al. Rev Invest Clin. 2003 Mar-Apr;55(2):138-42. Rev Invest Clin. 2003. PMID: 12827916
• Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.

  Hornberger J, Torriani FJ, Dieterich DT, Bräu N, Sulkowski MS, Torres MR, Green J, Patel K. Hornberger J, et al. J Clin Virol. 2006 Aug;36(4):283-91. doi: 10.1016/j.jcv.2006.04.008. Epub 2006 Jun 9. J Clin Virol. 2006. PMID: 16765638
• Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.

  Ferenci P. Ferenci P. Int J Clin Pract. 2003 Sep;57(7):610-5. Int J Clin Pract. 2003. PMID: 14529063 Review.
• [Interferon therapy for hepatitis B and C].

  Iino S. Iino S. Nihon Rinsho. 2007 Feb 28;65 Suppl 2 Pt. 1:559-63. Nihon Rinsho. 2007. PMID: 17455681 Review. Japanese. No abstract available.